The development and optimization of an efficient conjugation process involves identifying the critical quality attributes and monitoring critical process parameters.
Jesse Novak
Advertisement
Jesse Novak is a bioconjugation scientist at Abzena.
Articles by Jesse Novak
Advertisement
Latest Updated Articles
QbD in the Development of ADCs with PBD Dimer WarheadsSeptember 1st 2018
Advertisement
Advertisement
Trending on BioPharm International
1
FDA Accepts BLA for Formycon and Zydus’ FYB206, the First Publicly Announced Keytruda Biosimilar Under Review
2
FDA Rare Disease Framework Initiative: What It Means for Drug and Biologic Development
3
FDA Expands Anktiva Approval to Papillary-Only BCG-Unresponsive Bladder Cancer
4
Lilly's Mirikizumab (Omvoh) Hits New IBD Remission Goals
5